Clinical bottom line
Optimizing iron chelation therapy in patients with thalassemia-associated cardiomyopathy is a critical strategy to reduce iron overload–related cardiac damage and improve cardiovascular outcomes. Individualized regimens combining oral and subcutaneous chelators, tailored to iron burden and patient tolerance, may enhance efficacy and adherence. While iron chelation is established as essential to prevent cardiac complications, emerging insights into therapy personalization and its systemic effects, including on endocrine function and the gut microbiome, warrant integration into clinical practice. However, evidence gaps remain regarding long-term cardiovascular outcome data and optimal monitoring protocols.
What the evidence shows
Iron overload is the principal driver of cardiomyopathy in thalassemia major due to repeated transfusions, leading to progressive myocardial iron deposition and dysfunction. Iron chelation therapy (ICT) remains the cornerstone intervention to mitigate this risk by facilitating iron removal and preventing cardiac failure (Varoğlu et al., 2011). Multiple chelators are available, including oral agents such as deferasirox and deferiprone, and subcutaneous deferoxamine, with differing efficacy and safety profiles.
Comparative studies suggest that combination therapy using oral and subcutaneous chelators may improve iron clearance and cardiac outcomes compared to monotherapy, particularly in patients with high iron burden (Babrs et al., 2013). Oral chelators improve adherence due to ease of administration, but subcutaneous deferoxamine remains important in certain cases for effective myocardial iron removal (Uygun et al., 2013). Individualized therapy plans that consider patient-specific factors, iron load, and side effect profiles are increasingly advocated (Kontoghiorghes et al., 2009).
Beyond direct cardiac effects, iron chelation impacts systemic physiology relevant to cardiovascular health. For example, optimized ICT has been linked to improved growth and endocrine function in thalassemia patients, which may indirectly influence cardiovascular risk (Aydinok et al., 2026). Additionally, recent data highlight the influence of iron chelation on the gut microbiome, which could modulate systemic inflammation and cardiovascular health, though these findings remain preliminary (Deumić et al., 2025).
Serum ferritin remains a widely used biomarker to guide ICT initiation and adjustment, with elevated levels correlating with increased cardiac risk (Wasim et al., 2021). However, ferritin is an imperfect surrogate for myocardial iron, and cardiac MRI T2* imaging is the preferred modality for assessing myocardial iron load and guiding therapy intensity.
Caveats and uncertainty
Despite consensus on the importance of ICT, robust randomized controlled trials specifically evaluating long-term cardiovascular outcomes in thalassemia-associated cardiomyopathy are limited. Most evidence derives from observational cohorts and expert consensus, underscoring the need for prospective studies to define optimal chelation regimens and monitoring strategies.
The heterogeneity of thalassemia populations, variability in chelator pharmacokinetics, and patient adherence challenges complicate interpretation of efficacy data. Side effects such as gastrointestinal intolerance, neutropenia, and auditory or ocular toxicity require careful monitoring and may limit therapy options (Babrs et al., 2013).
Emerging data on ICT’s effects on the gut microbiome and endocrine function are intriguing but remain hypothesis-generating. Their direct impact on cardiovascular outcomes is not yet established and requires further validation (Deumić et al., 2025; Aydinok et al., 2026).
Finally, access to advanced cardiac imaging and chelation agents varies globally, which may affect the generalizability of findings and implementation of optimized ICT protocols.
How this may change practice
Clinicians managing thalassemia patients should prioritize early and aggressive iron chelation tailored to individual iron burden, using cardiac MRI T2* to guide therapy intensity and monitor response. Combination chelation regimens may be considered in patients with persistent myocardial iron overload or suboptimal response to monotherapy.
Monitoring for and managing ICT-related toxicities is essential to maintain adherence and optimize outcomes. Incorporating assessments of endocrine function and considering potential systemic effects of iron chelation may provide a more holistic approach to patient care.
Awareness of emerging research on the gut microbiome’s role may prompt future adjunctive strategies to modulate systemic inflammation and cardiovascular risk, pending further evidence.
Overall, a multidisciplinary approach involving hematologists, cardiologists, and endocrinologists is recommended to optimize cardiovascular outcomes in thalassemia-associated cardiomyopathy through personalized iron chelation therapy.